We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalEBIO: Epoch Pharmaceuticals

Previous 10 Next 10 
To: shearson who wrote (20)11/4/2002 6:38:23 PM
From: tuck
   of 33
I will be listening to this CC. I believe this past and next two quarters are vital to EBIO. They said in a recent PR that R. A. Welch of NCI would be presenting at two conferences in October, regarding the use of Eclipse probes in RT PCR for SNP analysis. The conference in Iceland doesn't publish the abstracts. The ASHG does, but I could find only one abstract by an R. welch. He seems to be with the NCI and is involved with SNPs, but the abstract makes only the vaguest reference to the assays, certainly nothing about Eclipse probes.

Can't find any reference to them on the NCI SNP pages, either. None of this has stopped EBIO from making an impressive bounce from the under a buck area during these two conferences, and I missed my chance to pick some cheap EBIO up by waiting for it to go under $.80 again.

After tomorrow, I will decide how much I want to chase it.

Cheers, Tuck

Share RecommendKeepReplyMark as Last Read

To: mopgcw who wrote (19)11/5/2002 3:58:41 PM
From: tuck
   of 33
Conference call notes:

Message 18196920

Cheers, Tuck

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: tuck who wrote (22)12/11/2002 8:23:46 AM
From: dalroi
   of 33
No new dillution :-)


Epoch Biosciences Applies to Transfer to Nasdaq SmallCap Market

BOTHELL, Wash., Dec. 11 /PRNewswire/ --
Epoch Biosciences, Inc. (NASDAQ:EBIO), a provider of proprietary products
that accelerate genomic analysis, announced that it has applied to The Nasdaq
Stock Market, Inc. to transfer the listing of its common stock from the Nasdaq
National Market to the Nasdaq SmallCap Market.
The company meets all the requirements of the Nasdaq National Market
except for the new $10 million minimum stockholders' equity standard under
Marketplace Rule 4450(a)(3). In its quarterly report on Form 10-Q for the
period ended September 30, 2002, the Company reported stockholders' equity of
approximately $8.7 million.
The company expects to receive Nasdaq's approval decision within the next
ten days and will maintain its current National Market status pending approval
of the transfer application. The company believes that it meets all listing
requirements of the Nasdaq SmallCap Market and anticipates approval of the
transfer. The company's common stock will continue to be traded under the
symbol "EBIO".
William G. Gerber, chief executive officer, stated, "We believe the
voluntary move to the Nasdaq SmallCap Market is in the best interest of our
shareholders and is preferable to raising additional equity in order to meet
the new stockholders equity standard. This move will allow us to continue to
focus on the fundamentals of our business, which we believe is the best way to
drive shareholder value

Share RecommendKeepReplyMark as Last Read

From: shearson2/24/2003 5:57:02 PM
   of 33
Live Conference Call & Webcast of Epoch BioSciences’ Q4 2002 Earnings.

Epoch BioSciences, Inc. holds a live webcast of their Q4 Earnings conference call. This takes place at 11:00 AM EST on Tuesday, February 25th, 2003 at the following link:

If you miss the live webcast, an archive will be available for 45 days at the same link as above.

To access the conference call dial 1-888-881-4892 or 1-416-640-4127. For the call replay dial 1-877-289-8525 or 1-416-640-1917 and enter passcode 238183#. The replay will be available for 1 week following the call.

Epoch Biosciences, Inc., formerly Epoch Pharmaceuticals, Inc., is developing and commercializing proprietary technologies to enhance the study of genes. Its scientists are applying their expertise in nucleic acid chemistry to develop products that improve methods of studying the genetic sequence (genomes) of humans, animals and plants.

ViaVid Broadcasting, Inc. provides teleconferencing and webcasting services to corporate clients throughout North America. These services utilize systems that integrate traditional telephony technology with powerful streaming media technology and Web-based tools. From a simple conference call to a dynamic online presentation, our clients are able to choose the communication solution that best meets their unique needs. ViaVid's communications expertise and in-house technology allows the company to provide these services on a very cost competitive basis.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: shearson who wrote (24)9/17/2003 8:22:00 AM
From: dalroi
   of 33
further on track

BOTHELL, Wash., Sept. 17 /PRNewswire-FirstCall/ -- Epoch Biosciences, Inc.
(Nasdaq: EBIO), a provider of proprietary products that accelerate genomic
analysis, announced it has entered into a worldwide non-exclusive license
agreement with Applied Biosystems Group (NYSE:ABI), an Applera Corporation
business, for its Eclipse(TM) Dark Quencher technology.

As part of the license and supply agreement, Epoch Biosciences will supply
Applied Biosystems its Eclipse Dark Quencher for incorporation into TaqMan(R)
probes for use in 5' nuclease assays. The license covers use of the quencher
technology for detection of microorganisms in the environment. The use of the
Eclipse Dark Quencher on TaqMan probes expands the utility of Epoch's quencher
technology into the field of environmental testing.

The license allows Applied Biosystems to manufacture, sell and distribute
TaqMan(R) probes that carry Epoch's quencher. Under the license agreement,
Epoch will receive license fees and royalties on Applied Biosystems' sales to
purchasers of such licensed products.

William G. Gerber, M.D., chief executive officer of Epoch, said, "We have
worked with Applied Biosystems for over four years and are pleased that they
have chosen to expand this important business relationship. Applied
Biosystems has extensive experience with Epoch technology and recognizes the
value it brings to its TaqMan(R) products. This is the kind of value-added
contribution we believe we can bring to partners and customers who place a
premium on performance."

Eclipse Dark Quencher

The Eclipse Dark Quencher is a pioneering technology developed by Epoch
Biosciences that when attached with a fluorescent dye to a DNA probe,
suppresses the signal generated by the dye until the probe binds to its target
DNA. It offers higher sensitivity in real-time PCR probes due to lower
background fluorescence, is applicable in a broad range of detection systems,
quenches of a broader dye emission spectra range, and is compatible with
simple and robust DNA synthesis procedures.

The Eclipse Dark Quencher is currently incorporated into MGB Eclipse(TM)
Probe Systems distributed for Epoch by Amersham Biosciences, in other
TaqMan(R) products sold by Applied Biosystems, in the Invader System sold by
Third Wave Technologies, and in QuantiTect gene expression assays sold by
QIAGEN. The Eclipse Dark Quencher is also licensed to Takara for use in
real-time PCR detection assays and is distributed by Glen Research for sale
into the research community.

Previous Applied Biosystems and Epoch Technology Licensing Agreements

Epoch has previously licensed its MGB(TM) and Eclipse Dark Quencher
technologies to Applied Biosystems for use in 5' nuclease real-time PCR
assays. The original agreements and subsequent modifications are detailed in
Epoch's Form 10-K and other filings

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

From: michael_f_murphy9/28/2003 2:27:27 AM
   of 33
Epoch Biosciences fails to win DOD contract
Friday September 26, 6:15 pm ET

LOS ANGELES, Sept 26 (Reuters) - Epoch Biosciences Inc. (NasdaqSC:EBIO - News), a provider of products that accelerate genomic analysis, on Friday said it did not win a U.S. Department of Defense contract for a biological agent identification system.
Epoch, based in Bothell, Washington, was a finalist in the competition for the program.

The company said it did not include revenue from the DOD project in its forecasts and its outlook for the fiscal year is unchanged.

Shares of Epoch fell 19 percent to close at $2.89 on Nasdaq

Share RecommendKeepReplyMark as Last Read

To: dalroi who wrote (25)10/6/2003 10:12:01 AM
From: tuck
   of 33
"further on track"

But off track elsewhere. I've been wondering if EBIO will ever break out its sales from the Amersham and Qiagen agreements -- and now ABI, too -- and here I have one third of my answer. Given that this was hinted at in August, the stock is handling the news well today . . .

>>BOTHELL, Wash., Oct. 6 /PRNewswire-FirstCall/ -- Epoch Biosciences, Inc. (Nasdaq: EBIO - News), a provider of proprietary products that accelerate genomic analysis, today announced that the Company had terminated a distribution and licensing agreement with Amersham Biosciences, the life sciences business of Amersham plc (LSE: NYSE: OSE: AHM). The pact, established in 2002, pertained to the marketing of Epoch's MGB Eclipse(TM) Probe Systems by Amersham to the research market worldwide.

William G. Gerber, Chief Executive Officer of Epoch, said, "We were very disappointed that Amersham failed to meet contractually established sales minimums and regret that our recent discussions did not produce a solution satisfactory to Epoch. We decided to focus our energy on programs and partnerships that are tracking to plan and generating growing revenues. We are in discussions with other potential distribution partners for the MGB Eclipse product line, and are pleased at the level of interest being shown. In parallel, we are encouraged by increasing direct sales of our Assay Validated Probe product to pharmaceutical and biotechnology companies."

In 2002, Epoch and Amersham entered into an agreement under which Amersham became the exclusive worldwide sales, marketing and distribution partner to the research field of Epoch's MGB Eclipse Probe Systems for SNPs, and the co-exclusive worldwide sales and marketing partner to the research field for gene expression. In early August 2003, Epoch disclosed that Amersham's sales of custom and catalogue MGB Eclipse Probe Systems to end-users had not grown as rapidly as expected, that Amersham was unlikely to achieve minimum sales levels provided for in the agreement between the companies, and that discussions had been initiated with Amersham about the rate of end-user sales growth and the related contractual terms. The company further disclosed in August that it anticipated revenues from Amersham would be insignificant for the balance of 2003 and reduced its projected revenues for full year 2003 to between $8.5 and $9.5 million. Today's announcement does not change the guidance provided in August.

In October 2002, Epoch and QIAGEN N.V. entered into a license and supply agreement under which QIAGEN became the co-exclusive worldwide sales, marketing and distribution partner to the research field of MGB Eclipse probe products for gene expression. QIAGEN launched its QuantiTect Gene Expression Assays in May 2003 for catalogue products, and in September 2003 for custom products. Customers can visit to order QuantiTect Gene Expression Assays from QIAGEN.<<


Cheers, Tuck

Share RecommendKeepReplyMark as Last Read

To: dalroi who wrote (23)9/8/2004 1:48:28 PM
From: tuck
   of 33
EBIO being munched by NGEN, and the rationale for anyone is hard to figure. Perhaps the Grace Brothers, and Dr. Craves, the original CEO, current chairman and Bay City Capital principal, cashed in their cheapest options ($.50) by last year. And started looking for a way out. The rest of their options, with some years left on them, are for much higher prices, so they write those off or hope NGEN actually survives -- which I doubt. But they'd still walk away with a healthy profit. EBIO shareholders, on the other hand, would need to have bought under $2 to get much. Even Gerber doesn't get much here. I wonder if other shareholders would fight the deal. If I'm right . . . Bay City and The Grace Bros. own about 40% of the company, so it would have to be a united front.

You still hold any, Stefaan? I'll be looking to get my Mom out of her shares soon. Don't like the deal, nor NGEN's prospects.

Cheers, Tuck

Share RecommendKeepReplyMark as Last Read

From: more1008/13/2015 5:36:30 AM
   of 33
$EBIO closed up 74.79% on Wednesday, on 29.65 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Share RecommendKeepReplyMark as Last Read

From: more1008/14/2015 5:39:53 AM
   of 33
$EBIO closed up 22.25 percent on Thursday, August 13, 2015, on 26.47 times normal volume. still watching

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10